Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 2019

View Archived Issues

CXCL10 arises as a potential therapeutic target for treating motor neuron disease

Sangamo Therapeutics presents preliminary data from phase I/II study of ST-400

MEDS-433 demonstrates promising antileukemic activity and limited toxicity in vivo

First data presented for XmAb-13676 in refractory/relapsed NHL and CLL

ALDH2 and Alzheimer's

Getting, and keeping, antitumor T cells energized

First-in-human findings presented for CC-93269

First transgenic animal model for IRF4-induced lymphoid malignancy

Phase I study of Metablok achieves primary endpoints

Interim data presented from phase I/II study of RGX-121

Boehringer Ingelheim announces discontinuation of development of BI-1467335 for NASH

First patients dosed in phase I clinical program of CTI-1601 for treatment of Friedreich's ataxia

First patient dosed in MAESTRO-NAFLD-1 phase III study of resmetirom

Initiation of first-in-human study of ANLE-138b

Medivir initiates phase II study of remetinostat in patients with squamous cell carcinoma

Jiangsu Chia Tai Tianqing Pharmaceutical Group, Medshine Discovery patent anti-HBV agents

e-Therapeutics identifies new IDO-1 and/or TDO inhibitors

Corbus Pharmaceuticals describes new cannabinoid CB2 receptor agonists

New SLC10A2/SLC10A1 inhibitors identified at Albireo

Medshine Discovery discloses ACC1/ACC2 inhibitors

New autoinflammatory disease linked to RIPK1 gene variants

European Commission approves Rinvoq for rheumatoid arthritis

Inventiva reports phase IIa results on odiparcil for MPS VI

NicOx reports data from phase II study of NCX-4251 for blepharitis

Kadcyla approved in E.U. for adjuvant treatment of HER2-positive early breast cancer

Rezolute reports phase I results for ultra long-acting basal insulin AB-101

FDA grants accelerated approval to Padcev for urothelial cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...